Clinical development of the GnRH agonist leuprolide acetate depot

Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive trea...

Full description

Saved in:
Bibliographic Details
Main Author: Kristof Chwalisz, M.D., Ph.D (Author)
Format: Book
Published: Elsevier, 2023-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d7d62ce674c943f8b7b81c9f9dc295c6
042 |a dc 
100 1 0 |a Kristof Chwalisz, M.D., Ph.D.  |e author 
245 0 0 |a Clinical development of the GnRH agonist leuprolide acetate depot 
260 |b Elsevier,   |c 2023-06-01T00:00:00Z. 
500 |a 2666-3341 
500 |a 10.1016/j.xfre.2022.11.011 
520 |a Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive treatments in men, women, and children, which are available in the United States and globally. This mini review aims to summarize the key clinical studies that led to regulatory approval of leuprolide acetate depot suspension for injection. 
546 |a EN 
690 |a Diseases of the genitourinary system. Urology 
690 |a RC870-923 
690 |a Gynecology and obstetrics 
690 |a RG1-991 
655 7 |a article  |2 local 
786 0 |n F&S Reports, Vol 4, Iss 2, Pp 33-39 (2023) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2666334122001222 
787 0 |n https://doaj.org/toc/2666-3341 
856 4 1 |u https://doaj.org/article/d7d62ce674c943f8b7b81c9f9dc295c6  |z Connect to this object online.